Navigation Links
Diabetes drug could treat leading cause of blindness
Date:5/7/2012

University of Texas Medical Branch at Galveston researchers have discovered that a drug already prescribed to millions of people with diabetes could also have another important use: treating one of the world's leading causes of blindness.

In laboratory rat and cell-culture experiments, the scientists found that metformin, which is commonly used to control blood sugar levels in type 2 diabetes, also substantially reduced the effects of uveitis, an inflammation of the tissues just below the outer surface of the eyeball. Uveitis causes 10 to 15 percent of all cases of blindness in the United States, and is responsible for an even higher proportion of blindness globally. The only treatment now available for the disorder is steroid therapy, which has serious side effects and cannot be used long-term.

"Uveitis has various causes the most common are infectious diseases and autoimmune disorders but they all produce inflammation within the eye," said UTMB professor Kota V. Ramana, senior author of a paper on the study now online in the journal Investigative Ophthalmology & Visual Science. "Metformin inhibits the process that causes that inflammation."

The scientists discovered metformin's efficacy when they tested it in rats given an endotoxin that mimicked the inflammatory effects of bacterial infection. The results showed clearly that metformin was a very effective anti-uveitis agent.

"We found that the drug is therapeutic as well as preventive if we gave our rats the drug beforehand, they didn't develop uveitis, and if we gave it after uveitis had developed, it was therapeutic," said UTMB professor Satish Srivastava, also an author of the IOVS paper. "Metformin's strong anti-inflammatory properties make this possible."

According to the researchers, metformin works by activating an enzyme called AMPK, which in turn damps down the activity of the protein NF-kappa B. The inhibition of NF-kappa B suppresses the production of inflammatory signaling molecules cytokines and chemokines needed to initiate and sustain uveitis.

Because metformin is already used so widely as a therapy for diabetes, the UTMB scientists believe that it has a good chance of being rapidly adopted as an anti-uveitis drug.

"I think after a few more pre-clinical studies are done, we can get this drug to patients in a shorter time than usual," Ramana said. "Its safety is already known, so all that we need to see is its efficacy in humans."


'/>"/>

Contact: Jim Kelly
jpkelly@utmb.edu
409-772-8791
University of Texas Medical Branch at Galveston
Source:Eurekalert

Related medicine news :

1. Study identifies possible protective blood factors against Type 2 diabetes
2. New research finds no association between white potato consumption (baked, boiled mashed) and obesity, Type 2 diabetes or systemic inflammation
3. Xenotransplantation as a therapy for type 1 diabetes
4. Value of Metformin, Insulin Combo for Type 2 Diabetes Questioned
5. Diabetes Groups Issue New Guidelines on Blood Sugar
6. Cellular pathway linked to diabetes, heart disease
7. Naturopathic care can improve blood sugar, mood in diabetes
8. Weight-Loss Surgery Beat Drugs for Cutting Diabetes in Very Obese
9. Common Plastics Chemical Might Boost Diabetes Risk
10. Mouse Study Hints at New Path for Diabetes Treatment
11. Disrupted Sleep May Raise Risk for Obesity, Diabetes: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... WHO: , Dr. Paul Thomas; Dr. Brian ... Medical doctors and PhD scientists will speak to the press on behalf of over ... of an independent vaccine safety commission. , WHERE: , Zenger Room, National Press ...
(Date:3/28/2017)... ... 2017 , ... Calibration, qualification, and the appropriate level of ... GMP and USP compliance. In a new webinar from METTLER TOLEDO entitled “ ... requirements are explained. The challenge is to determine how to put the ...
(Date:3/28/2017)... ... 28, 2017 , ... Neurotechnology , a provider of ... attendance tracking products: the new NCheck Cloud Bio Attendance cloud-based service and the ... face recognition to enable users to check in and out from anywhere via ...
(Date:3/28/2017)... ... March 28, 2017 , ... In its ... Success website has recently developed and published an informational resource that addresses frequently ... based on common inquiries the site’s team of third party administrator (TPA) contributors ...
(Date:3/28/2017)... ... March 28, 2017 , ... A minimally ... the “perfect smile.” The National Association of Dental Laboratories (NADL) is informing dentists ... be aware of when utilizing dental laboratories and technicians that create these veneers. ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... , March 27, 2017 FinancialBuzz.com News Commentary  ... According to a new report by ... America , grew 34 percent to $6.7 billion and can be ... (CAGR) over the next five years, from $6.7 billion in 2016, to ... that will be able to purchase cannabis without a doctor,s recommendation. Voters ...
(Date:3/27/2017)... /PRNewswire/ - INVICTUS MD STRATEGIES CORP. ("Invictus MD" or ... is pleased to announce it has received conditional approval ... TSX Venture Exchange.  Receiving the conditional ... significant achievements for Invictus-MD. Some of which include: ... Laboratories Inc. ("AB Labs"), a Licensed Producer under the ...
(Date:3/27/2017)... Calif. , March 27, 2017 The ... in the wealthiest countries have access to the latest ... countries like the US, many patients have inadequate or ... debts or skip therapy altogether. Access to modern cancer ... less affluent countries. The mission statements ...
Breaking Medicine Technology: